AR078411A1 - Compuesto de vinil imidazolilo y composicion farmaceutica que lo comprende - Google Patents
Compuesto de vinil imidazolilo y composicion farmaceutica que lo comprendeInfo
- Publication number
- AR078411A1 AR078411A1 ARP100101403A ARP100101403A AR078411A1 AR 078411 A1 AR078411 A1 AR 078411A1 AR P100101403 A ARP100101403 A AR P100101403A AR P100101403 A ARP100101403 A AR P100101403A AR 078411 A1 AR078411 A1 AR 078411A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- pharmaceutical composition
- imidazolil
- vinyl
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Un compuesto de vinil imidazolilo que es (E)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1H-indazol-3-il)vinil)-1H-pirazol-1-il)etanol, o una sal del mismo farmacéuticamente aceptable. Preferentemente, el compuesto es (R)-(E)-2(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1H-indazol-3-il)vinil)- 1H-pirazol-1-il)etanol, o una sal del mismo farmacéuticamente aceptable. Una composicion farmacéutica que comprende dicho compuesto o su sal en combinacion con un portador, diluyente o excipiente farmacéuticamente aceptable. Dicho compuesto o su sal es para uso en terapia, preferiblemente para el tratamiento de cáncer. Dicho cáncer se selecciona de cáncer de pulmon de célula no pequena, cáncer gástrico y mieloma multiple.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17629009P | 2009-05-07 | 2009-05-07 | |
| US30141610P | 2010-02-04 | 2010-02-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR078411A1 true AR078411A1 (es) | 2011-11-09 |
Family
ID=42238704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100101403A AR078411A1 (es) | 2009-05-07 | 2010-04-27 | Compuesto de vinil imidazolilo y composicion farmaceutica que lo comprende |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US8268869B2 (es) |
| EP (1) | EP2427449B1 (es) |
| JP (1) | JP5555314B2 (es) |
| KR (1) | KR101373910B1 (es) |
| CN (1) | CN102421769B (es) |
| AR (1) | AR078411A1 (es) |
| AU (1) | AU2010246114B2 (es) |
| BR (1) | BRPI1013748A2 (es) |
| CA (1) | CA2760535C (es) |
| CL (1) | CL2011002781A1 (es) |
| CO (1) | CO6450624A2 (es) |
| CR (1) | CR20110580A (es) |
| DK (1) | DK2427449T3 (es) |
| EA (1) | EA018149B1 (es) |
| EC (1) | ECSP11011441A (es) |
| ES (1) | ES2408117T3 (es) |
| HN (1) | HN2011002809A (es) |
| HR (1) | HRP20130323T1 (es) |
| IL (1) | IL216004A (es) |
| JO (1) | JO2860B1 (es) |
| MA (1) | MA33244B1 (es) |
| ME (1) | ME01462B (es) |
| MX (1) | MX2011011342A (es) |
| MY (1) | MY160390A (es) |
| NZ (1) | NZ595553A (es) |
| PE (2) | PE20120812A1 (es) |
| PL (1) | PL2427449T3 (es) |
| PT (1) | PT2427449E (es) |
| RS (1) | RS52795B (es) |
| SG (1) | SG175909A1 (es) |
| SI (1) | SI2427449T1 (es) |
| TW (1) | TWI382982B (es) |
| UA (1) | UA104756C2 (es) |
| WO (1) | WO2010129509A1 (es) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3062B1 (ar) * | 2010-10-05 | 2017-03-15 | Lilly Co Eli | R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| MX365214B (es) | 2012-03-08 | 2019-05-27 | Astellas Pharma Inc | Nuevo producto de fusion de fgfr3. |
| ES2984771T3 (es) | 2012-06-13 | 2024-10-31 | Incyte Holdings Corp | Compuestos tricíclicos sustituidos como inhibidores de FGFR |
| US20150203589A1 (en) | 2012-07-24 | 2015-07-23 | The Trustees Of Columbia University In The City Of New York | Fusion proteins and methods thereof |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| EP2968551B1 (en) | 2013-03-15 | 2021-05-05 | The Trustees of Columbia University in the City of New York | Fusion proteins and methods thereof |
| EA035095B1 (ru) | 2013-04-19 | 2020-04-27 | Инсайт Холдингс Корпорейшн | Бициклические гетероциклы в качестве ингибиторов fgfr |
| CN103819396B (zh) * | 2014-02-26 | 2016-06-15 | 四川大学 | 一种手性的1-（3,5-二氯吡啶-4-基）-乙醇的合成方法 |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| WO2016105517A1 (en) | 2014-12-23 | 2016-06-30 | The Trustees Of Columbia University In The City Of New York | Fusion proteins and methods thereof |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| EA038045B1 (ru) | 2015-02-20 | 2021-06-28 | Инсайт Корпорейшн | Бициклические гетероциклы в качестве ингибиторов fgfr |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| CN105906621A (zh) * | 2015-04-06 | 2016-08-31 | 四川百利药业有限责任公司 | 用作fgfr抑制剂的乙醇类化合物 |
| WO2016187767A1 (en) * | 2015-05-25 | 2016-12-01 | Hutchison Medipharma Limited | Pharmaceutical compositions and use thereof |
| CN107922349B (zh) * | 2015-08-07 | 2021-05-07 | 哈尔滨珍宝制药有限公司 | 作为fgfr和vegfr抑制剂的乙烯基化合物 |
| EP3339305B1 (en) | 2015-08-20 | 2022-05-04 | Zhejiang Hisun Pharmaceutical Co., Ltd | Indole derivative, preparation method thereof, and use thereof in pharmaceutical drug |
| CN107459519A (zh) | 2016-06-06 | 2017-12-12 | 上海艾力斯医药科技有限公司 | 稠合嘧啶哌啶环衍生物及其制备方法和应用 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| RS66310B1 (sr) | 2018-05-04 | 2025-01-31 | Incyte Corp | Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu |
| US11174257B2 (en) | 2018-05-04 | 2021-11-16 | Incyte Corporation | Salts of an FGFR inhibitor |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| PH12022550892A1 (en) | 2019-10-14 | 2023-05-03 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021088859A1 (zh) * | 2019-11-06 | 2021-05-14 | 暨南大学 | 吲唑类化合物及其药用组合物和应用 |
| AU2020395185A1 (en) | 2019-12-04 | 2022-06-02 | Incyte Corporation | Derivatives of an FGFR inhibitor |
| EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| US12441707B2 (en) | 2019-12-30 | 2025-10-14 | Tyra Biosciences, Inc. | Indazole compounds |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2022033472A1 (zh) * | 2020-08-11 | 2022-02-17 | 河南迈英诺医药科技有限公司 | Fgfr抑制剂化合物及其用途 |
| JP2024513575A (ja) | 2021-04-12 | 2024-03-26 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法 |
| WO2022261160A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| TW202313610A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之三環雜環 |
| CN116554148B (zh) * | 2022-12-13 | 2025-01-28 | 药康众拓(北京)医药科技有限公司 | 一种乙烯基吲唑类氘代fgfr抑制剂药物及用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6897231B2 (en) * | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| KR100732206B1 (ko) | 2000-09-11 | 2007-06-27 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 티로신 키나제 억제제로서의 퀴놀리논 유도체 |
| EP1447405A4 (en) * | 2001-10-17 | 2005-01-12 | Kirin Brewery | CHINOLIN OR CHINAZOLINE DERIVATIVES THAT PREVENT THE AUTOPHOSPHORYLATION OF RECEPTORS FOR THE FIBROBLAST GROWTH FACTOR |
| TW200406385A (en) * | 2002-05-31 | 2004-05-01 | Eisai Co Ltd | Pyrazole compound and pharmaceutical composition containing the same |
| DE10342503A1 (de) * | 2003-09-12 | 2005-04-14 | Merck Patent Gmbh | Benzyl-Benzimidazolylderivate |
| ATE404560T1 (de) | 2004-05-26 | 2008-08-15 | Pfizer | Indazol- und indolonderivative und deren verwendung als pharmazeutika |
| WO2007058626A1 (en) | 2005-11-16 | 2007-05-24 | S*Bio Pte Ltd | Indazole compounds |
| EP1963320A1 (en) * | 2005-12-07 | 2008-09-03 | OSI Pharmaceuticals, Inc. | Pyrrolopyridine kinase inhibiting compounds |
| CA2673095C (en) | 2006-12-20 | 2016-03-15 | Nerviano Medical Sciences S.R.L. | Indazole derivatives as kinase inhibitors for the treatment of cancer |
| US7737149B2 (en) * | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
| KR20100025553A (ko) | 2007-06-05 | 2010-03-09 | 쉐링 코포레이션 | 암 치료용 ｅｒｋ 억제제로서의 폴리사이클릭 인다졸 유도체 및 이의 용도 |
| DE102007028521A1 (de) | 2007-06-21 | 2008-12-24 | Merck Patent Gmbh | Indazolamidderivate |
| JP2011511005A (ja) * | 2008-02-04 | 2011-04-07 | オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド | ２−アミノピリジン系キナーゼ阻害薬 |
-
2010
- 2010-04-27 JO JO2010130A patent/JO2860B1/en active
- 2010-04-27 AR ARP100101403A patent/AR078411A1/es unknown
- 2010-04-29 TW TW099113702A patent/TWI382982B/zh not_active IP Right Cessation
- 2010-05-04 PT PT107174021T patent/PT2427449E/pt unknown
- 2010-05-04 PL PL10717402T patent/PL2427449T3/pl unknown
- 2010-05-04 RS RS20130207A patent/RS52795B/sr unknown
- 2010-05-04 ES ES10717402T patent/ES2408117T3/es active Active
- 2010-05-04 BR BRPI1013748A patent/BRPI1013748A2/pt not_active IP Right Cessation
- 2010-05-04 EA EA201171367A patent/EA018149B1/ru not_active IP Right Cessation
- 2010-05-04 PE PE2011001877A patent/PE20120812A1/es not_active Application Discontinuation
- 2010-05-04 ME MEP-2013-32A patent/ME01462B/me unknown
- 2010-05-04 MX MX2011011342A patent/MX2011011342A/es active IP Right Grant
- 2010-05-04 SG SG2011081627A patent/SG175909A1/en unknown
- 2010-05-04 PE PE2016000013A patent/PE20160124A1/es not_active Application Discontinuation
- 2010-05-04 NZ NZ595553A patent/NZ595553A/xx not_active IP Right Cessation
- 2010-05-04 HR HRP20130323AT patent/HRP20130323T1/hr unknown
- 2010-05-04 MA MA34312A patent/MA33244B1/fr unknown
- 2010-05-04 CN CN201080020264.3A patent/CN102421769B/zh not_active Expired - Fee Related
- 2010-05-04 DK DK10717402.1T patent/DK2427449T3/da active
- 2010-05-04 MY MYPI2011005296A patent/MY160390A/en unknown
- 2010-05-04 SI SI201030191T patent/SI2427449T1/sl unknown
- 2010-05-04 JP JP2012509889A patent/JP5555314B2/ja not_active Expired - Fee Related
- 2010-05-04 WO PCT/US2010/033487 patent/WO2010129509A1/en not_active Ceased
- 2010-05-04 UA UAA201112804A patent/UA104756C2/uk unknown
- 2010-05-04 CA CA2760535A patent/CA2760535C/en not_active Expired - Fee Related
- 2010-05-04 AU AU2010246114A patent/AU2010246114B2/en not_active Ceased
- 2010-05-04 KR KR1020117026320A patent/KR101373910B1/ko not_active Expired - Fee Related
- 2010-05-04 EP EP10717402A patent/EP2427449B1/en active Active
- 2010-05-04 US US12/773,186 patent/US8268869B2/en not_active Expired - Fee Related
-
2011
- 2011-10-21 HN HN2011002809A patent/HN2011002809A/es unknown
- 2011-10-27 IL IL216004A patent/IL216004A/en not_active IP Right Cessation
- 2011-11-04 CO CO11150245A patent/CO6450624A2/es active IP Right Grant
- 2011-11-07 CL CL2011002781A patent/CL2011002781A1/es unknown
- 2011-11-07 EC EC2011011441A patent/ECSP11011441A/es unknown
- 2011-11-07 CR CR20110580A patent/CR20110580A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR078411A1 (es) | Compuesto de vinil imidazolilo y composicion farmaceutica que lo comprende | |
| CL2013000884A1 (es) | El compuesto (r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol cristalino, modulador del factor de crecimiento de fibroblastos (fgf); composicion farmaceutica, util en el tratamiento del cancer. | |
| CL2009000228A1 (es) | Compuestos derivados de 7,8-dihidropirido[4,3-d]pirimidin con un sustituyente oximico, inhibidores de hsp90; y composicion farmaceutica que comprene a dichos compuestos. | |
| UA99621C2 (xx) | Похідні піридазинону$производные пиридазинона | |
| ECSP099436A (es) | Acilaminopirazoles como inhibidores de fgfr | |
| CL2008002129A1 (es) | Compuestos derivados de (1h-indazol-3-il)-amidas sustituidas, inhibidores de quinasa; composicion farmaceutica; procedimiento de preparacion; y uso del compuesto para el tratamiento del cancer. | |
| MX376856B (es) | Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1). | |
| CL2008002369A1 (es) | Compuestos derivados de piridin-3-il-oxipiridin-2-il-amino, inhibidores de alk5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del cancer. | |
| CU20160109A7 (es) | Compuestos de indazol como inhibidores de irak4 | |
| WO2009105513A8 (en) | Novel compounds and methods for therapy | |
| WO2009016072A3 (en) | A morpholinyl anthracycline derivative combined with protein kinase inhibitors | |
| ATE479687T1 (de) | Kinaseinhibitoren | |
| CL2009000906A1 (es) | Compuestos derivados de 4-imidazolil y 4-triazolil de 2-(6-(4-cicloalquilpiperazin-1-il)pirimidin-4-il)-1h-pirazol-3(2h)ona inhibidores de hif-prolil-4-hidroxilasas; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de enfermedades cardiovasculares, renales y hematologicas. | |
| EA201100334A1 (ru) | Бициклические производные триазола для лечения опухолей | |
| NO341679B1 (no) | Substituerte pyridylamidforbindelser, fremstilling av slike og farmasøytiske sammensetninger inneholdende slike, samt anvendelse som modulatorer av histamin H3-reseptoren | |
| AR120799A1 (es) | 2-[4-cloro-6-[2-[4-[[4-(hidroximetil)-1-piperidil]metil]fenil]etinil]-1-oxoisoindolin-2-il]-2-(6,7-dihidro-5h-pirrolo[1,2-c]imidazol-1-il)-n-tiazol-2-il-acetamida como inhibidor de egfr | |
| CL2007003251A1 (es) | Compuestos derivados de 1h-pirazoles sustituidos, inhibidores de reacciones catalizadas por una quinasa; su procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; uso de los compuestos principales, utiles en el tratamiento del cancer. | |
| MX2015012386A (es) | Inhibidores de la cinasa cdk9. | |
| DOP2018000134A (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer | |
| CL2018003107A1 (es) | Procedimiento para la preparación de derivados de 1-fenilo-1,2,4-triazol sustituidos por 5-hidroxialquilo | |
| EA201000613A1 (ru) | Тризамещенные пиперидины | |
| ES2531159T3 (es) | Compuestos y métodos para el tratamiento del cáncer | |
| EA201000611A1 (ru) | 4,4-дизамещенные пиперидины | |
| EA201000720A1 (ru) | 4,4-дизамещённые пиперидины как ингибиторы ренина | |
| NO20063943L (no) | Kombinasjon av voriconazol og en antifungal CYP2C19 inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |